hypothesize that patients with symptomatic PAD will express several diagnostic cardiac markers of CAD in the absence of acute coronary syndrome (ACS).
Objective: This study sought to assess clinical outcomes of a single-center experience following drug-coated balloon (DCB) angioplasty in patients with TransAtlantic Inter-Society Consensus (TASC) II types C and D femoropopliteal peripheral artery disease (PAD).
Methods: This retrospective study evaluated the patients who underwent DCB angioplasty for femoropopliteal PAD at our center between 2010 and 2016, with at least 1 year of follow-up. Of 424 patients with DCB-treated femoropopliteal disease, 152 were classified as TASC II type C or D. Demographics and comorbidities including age, sex, smoking status, hypertension, diabetes, and dialysis were recorded, alongside intervention details. Freedom from target lesion revascularization (TLR) within 1 year of interventionddefined as requiring bypass surgery or repeated percutaneous endovascular interventiondwas the primary outcome. Secondary outcomes included major above-knee or belowknee amputation and death.
Results: We analyzed 152 patients, excluding 13 because of immediate reintervention, amputation, bypass surgery, or death within 30 days of intervention. Of these 139 patients, 92 (66%) were type C and 47 (34%) were type D, with a mean treated lesion length of 18 6 6 cm; 75% were current or past smokers, 83% had hypertension, 63% had diabetes, and 5% were on dialysis. The dominant indication (45%) was severe claudication (Rutherford class 3), the remaining 55% being Rutherford class 4 to 6. De novo lesions made up 62% of cases, with in-stent stenosis or occlusions and recurrent stenosis each representing 19%; 27% of lesions were simultaneously treated with a short bare stent or drug-eluting stent, and 46% had multifocal disease treated as part of the procedure. At 1 year, 2% of patients had major amputation, and mortality was 12%. TLR at 1 year was 24% (33/139; Fig) .
Conclusions: Freedom from TLR in this cohort of patients with TASC II types C and D PAD was found to be 88% at 6 months and 76% at 12 months. Our initial results show that DCBs have a promising role in management of complex femoropopliteal disease.
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